Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is renowned for its innovative therapies in the field of rare diseases. Founded in 1992, Alexion has made significant strides in developing life-changing treatments, particularly in the areas of neurology, nephrology, and immunology.
The company’s flagship products, including Soliris and Ultomiris, are unique in their ability to target complement-mediated diseases, setting new standards in patient care. With a strong market position, Alexion has achieved notable milestones, such as expanding its global reach across North America, Europe, and Asia. Committed to advancing science and improving patient outcomes, Alexion Pharmaceuticals continues to be a pivotal player in the biopharmaceutical industry.
+56 vs industry average
Alexion Pharmaceuticals, Inc.’s score of 95 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alexion Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Alexion Pharmaceuticals, Inc. yet.
Alexion Pharmaceuticals, Inc.'s reported carbon emissions
Alexion Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of AstraZeneca PLC, any climate commitments or emissions data may be inherited from its parent company.
AstraZeneca has set ambitious climate targets, which include commitments to reduce greenhouse gas emissions across its operations. These targets are cascaded to Alexion Pharmaceuticals, reflecting a broader corporate strategy aimed at sustainability and climate resilience.
While specific reduction targets for Alexion are not detailed, AstraZeneca's initiatives include participation in the Science Based Targets initiative (SBTi) and commitments to renewable energy through the RE100 initiative. These efforts underscore a commitment to reducing Scope 1, 2, and 3 emissions, although specific figures for Alexion are not disclosed.
In summary, while Alexion Pharmaceuticals, Inc. does not currently report its own emissions data, it aligns with the climate commitments and reduction strategies of its parent company, AstraZeneca PLC, focusing on sustainability and emissions reduction across the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alexion Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alexion Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Alexion Pharmaceuticals, Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project